Skip to content
value.today

Menlo Therapeutics, Inc.

Total raised
$51 M
1 round on record
Latest round
$51 M
Jul 2017
First round on record
Jul 2017
Today
Went public
See the company page

Menlo Therapeutics, Inc. is listed today as Yarrow Bioscience, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Menlo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2023$88 MPrivate placement after listing$50 to $250 million

Menlo Therapeutics, Inc.: Private sale, Nov 2023

Investors in this round

19 investors had bought by the notice of Nov 16, 2023: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Menlo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$88 M of $88 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,039,090
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Domzalski · Executive Officer, Director
  • Iain Stuart · Executive Officer
  • Mutya Harsch · Executive Officer
  • Tyler Zeronda · Executive Officer
  • Anthony Bruno · Director
  • Elisabeth Sandoval · Director
  • Patrick Lepore · Director
  • Sharon Barbari · Director
  • Steven Basta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeSci Capital LLC (CRD 168404) · New York, New YorkSold in CA, CT, FL, IL, MA, NY

Signed by David T. Domzalski, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 16, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2017$51 MNo. 1$50 to $250 million

Menlo Therapeutics, Inc.: Raise no. 1, Jul 2017

Investors in this round

11 investors had bought by the notice of Jul 28, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Menlo Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$51 M of $51 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Steven L. Basta · Executive Officer, Director
  • Aaron L. Royston · Director
  • Albert L. Cha · Director
  • David L. Collier · Director
  • John L. Creecy · Director
  • Ketan L. Patel · Director
  • Scott L. Whitcup · Director
  • Ted L. Ebel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven L. Basta, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 28, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Yarrow Bioscience, Inc., its revenue in fiscal 2025 came from these product and service lines: Royalty revenues $570,000 (95%).

    Annual report (SEC XBRL) · Dec 2025

  • Menlo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).

    SEC Form D · Nov 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2023

Products and services#

No products or services of Menlo Therapeutics, Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Menlo Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
CMEA Ventures VII LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cmea Ventures VII (parallel) LPVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Presidio Partners 2007 GP, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Remeditex Ventures LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
venBio Global Strategic Fund II L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 11 investors.

Largest shareholders today

Institutions holding Yarrow Bioscience, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Menlo Therapeutics, Inc.
NameRoleNamed in
David DomzalskiExecutive officerNov 2023
Iain StuartExecutive officerNov 2023
Mutya HarschExecutive officerNov 2023
Tyler ZerondaExecutive officerNov 2023
Steven L. BastaExecutive officerJul 2017
Anthony BrunoDirectorNov 2023
David DomzalskiDirectorNov 2023
Elisabeth SandovalDirectorNov 2023
Patrick LeporeDirectorNov 2023
Sharon BarbariDirectorNov 2023
Steven BastaDirectorNov 2023
Aaron L. RoystonDirectorJul 2017
Albert L. ChaDirectorJul 2017
David L. CollierDirectorJul 2017
John L. CreecyDirectorJul 2017
Ketan L. PatelDirectorJul 2017
Scott L. WhitcupDirectorJul 2017
Steven L. BastaDirectorJul 2017
Ted L. EbelDirectorJul 2017

Went public since 2018. Its SEC number is that of a company listed on a stock exchange.